Pharmaceutical

Opinion: Clinical trials for Alzheimer’s treatments nee...

CMS must encourage the Down syndrome community to participate in clinical trials...

STAT+: NIH grant recipients often fail to disclose agen...

The NIH may be the largest public funder of biomedical research in the U.S., but...

STAT+: Gilead foresees more growth in its HIV drugs

Gilead's CEO believes the foundation of the company will continue to be its HIV ...

Listen: Lilly’s Alzheimer’s success, a milestone FDA ap...

What's the future of Alzheimer's disease treatment? How do you pivot from a pand...

‘Are we better off with the information?’: Experts spar...

“You can't make an asymptomatic person feel better," cardiologist Rita Redberg s...

STAT+: Senator pushes NIH for ‘formal’ review of Covid ...

Republicans continued to press top health officials on the coronavirus response ...

STAT+: NIH systems for non-human primate research fall ...

“Now is the time to strengthen the systems we need for nonhuman primate research...

Understanding the current and future state of complex h...

The recent proliferation of digital health has led to data privacy concerns arou...

FDA grants GSK first-ever approval for RSV vaccine

Amidst steep competition, GSK’s Arexvy becomes the first approved vaccine worldw...

Forge Biologics and Labcorp partner for gene therapies ...

The collaboration will reduce constraints related to analytical development and ...

ARTHEx Biotech raises funds to advance DM1 therapy to c...

ATX-01 has a dual mechanism of action that targets toxic DMPK and MBNL proteins.

Roche opens new institute to advance research in human ...

Human model systems are tiny 2D or 3D living replicas of human tissues and organ...

US FDA approves Kamada’s application to manufacture Cyt...

The regulatory approval represents the completion of the Cytogam technology tran...

Magenta Therapeutics and Dianthus agree to merge operat...

The merger and associated financing are scheduled to be completed by the third q...

Vertex secures FDA clearance for infants’ cystic fibros...

The approval allows KALYDECO to be used in infants who have at least one mutatio...

Bristol Myers Squibb’s Breyanzi receives EC approval to...

Breyanzi’s approval is based on the data obtained from the Phase III TRANSFORM t...